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The paper, published recently in Nature by the group of Francisco
Quintana,1 describes the anti-inflammatory astrocytes, activity of
which is tuned by the microbiotome and meningeal natural killer
(NK) cells.
Astrocytes are a sub-type of neuroglia responsible for homo-
eostasis and defence of the nervous system. Pathological reactions
of neuroglial cells in various neurological disorders have been
identified and characterised in the end of the 19th century; in
particular hypertrophy of astrocytes was recognised as a frequent
morbid change accompanying diseases of the central nervous
system (CNS). Subsequently, hyperplasia and proliferation of
astrocytes in response to polyetiological insults to the nervous
tissue were formalised in a concept of reactive astrogliosis, which
was considered to be a universal sign of neuropathology, a kind of
stereotypic response that provided “splint” (as it was called by
Wilder Penfield) to the nervous tissue and filled the spaces left by
disintegrating neurons; the ultimate outcome of astrogliosis was a
formation of a glial scar.2 This view has dominated neurological
thoughts for almost a century; however, recent two decades led to
a fundamental revision of principles of astrogliopathology.3,4 First,
it has been found that various diseases including, for instance,
neuropsychiatric disease or various leucomalacia are associated
with or even driven by astroglial asthenia, atrophy or loss of
function. Second, it appeared that astrogliosis generates multiple
reactive phenotypes, characterised by distinct gene expression
signatures and functional outcomes3,5; reactive astrocytes often
act as neuroprotectors but sometimes acquire deleterious
features. Inhibition of reactive astrogliosis may either exacerbate
or alleviate neurological outcome. Various reactive or asthenic
astrocytic phenotypes may develop sequentially or simultaneously
in different brain regions under the same pathological context.
Otherwise, distinct pathological forms of astrocytes can be linked
to the disease stage, reflecting a high degree of pathological
plasticity of astroglia. Astrocytic phenotypes and functions are also
affected by ageing, while the remodelling of astrocytes in the old
CNS can define the susceptibility of the nervous tissue to age-
dependent neurodegenerative diseases.
A previously unknown population of anti-inflammatory astro-
cytes has been identified and characterised in the mouse brain by
a combination of state-of-the-art techniques including single-cell
RNA sequencing, high-throughput flow cytometry screening, and
CRISPR–Cas9-based genetic manipulations.1 These specialised
astrocytes express the lysosomal associated protein 1 (LAMP1)
and the death receptor activator TRAIL (encoded by Tnfsf10 gene),
which both confer anti-inflammatory capabilities. The TRAIL
stands for tumour necrosis factor-related apoptosis-inducing
ligand; it belongs to the family of tumour necrosis factors, which
instigate apoptosis through engaging death receptors and their
downstream molecular cascades. The TRAIL-positive astrocytes
limit neuroinflammation in the experimental autoimmune ence-
phalomyelitis (EAE) by initiating apoptotic death of infiltrating T-
lymphocytes. Specific inactivation of TRAIL in astrocytes by
inactivating the Tnfsf10 gene with Gfap-driven CRISPR–Cas9
lentivirus aggravated EAE progression. The anti-inflammatory
TRAIL astrocytes seem to populate the spinal cord; they were
not identified in the cortex and cerebellum.
The TRAIL-positive astrocytes are located close to meninges in
mice and in humans; notably, their population is decreased in
tissues obtained from patients with diagnosed multiple sclerosis.
The anti-inflammatory astrocytes are regulated by NK cells
residing in meninges (Fig. 1); this regulation is mediated by
interferon-γ (IFN-γ). The NK cells are a part of innate tissue
immunity; these cells are large granular lymphocytes that are
swiftly recruited in response to insults. The NK cells are cytolytic
and secrete various cytokines; these cells are known to limit
neuroinflammation, particularly in the context of multiple
sclerosis. The NK cells are heterogeneous; a sub-population of
them produce and secrete IFN-γ, a relatively small molecule (m.w.
~16.8 kDa), which can diffuse through subarachnoid cerebrospinal
fluid and reach astrocytic endfeet. When perceived by astrocytic
receptors, IFN-γ launches the yet unknown signalling cascade that
upregulates TRAIL expression and hence stimulates anti-
inflammatory astrocyte defence. The state of NK cells is modulated
by systemic factors, and in particular, the production of IFN-γ
depends on the gut flora. Depletion of the microbiome by
treatment with antibiotics resulted in a substantial decrease of the
IFN-γ producing meningeal NK cells, although their total number
remains unchanged. Such a reduction translates into down-
regulation of the anti-inflammatory astrocytes, thus presumably
limiting their protective potential.
Identification of a specialised sub-type of anti-inflammatory
astrocytes further widens the repertoire or astrocytic capabilities to
restrain diseases and adds a new dimension to our understanding of
astroglial plasticity in the healthy and diseased brain. The variations
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in the state of anti-inflammatory astrocytes are regulated by NK
meningeal cells, which, in their turn, are controlled by systemic
immunity and in particular, by the gut microbiome. The gut—NK
cell—astrocytes axis clearly demonstrates the fundamental role of
systemic factors in the regulation of various aspects of CNS function.
The status of the gut–brain axis also defines the vulnerability of the
nervous tissue to multiple diseases, as indeed deficiency in anti-
inflammatory astrocytes may be directly linked to neuroinflamma-
tory disorders such as multiple sclerosis. Manipulation with the gut
microbiome may, therefore, represent a potentially powerful
therapeutic strategy. It also remains to be seen whether anti-
inflammatory astrocytes operate only in the spinal cord or similar
cells populate other brain parts; it is also imperative to discern
morphological and physiological peculiarities of these astrocytes.
Conceptually, the state of neuroglia defines the brain vulner-
ability to pathology. In this respect, all types of neuroglia seem to
work in concert to keep the homoeostasis of the nervous tissue
intact in the face of ongoing environmental challenges. Insults to
the brain similarly trigger a concerted response of all neuroglial
cells aimed at resolution of pathology, regeneration and return to
the physiological homoeostatic state. Neuroglial failure at every
stage facilitates neuropathology, whereas deficient defence
promotes the death of neural tissue. Neuroglia, therefore,
represents a primary target for preventive medicine as manipula-
tion with protective glial phenotypes may arrest or retard
pathological evolution. The discovery of a new set of astroglia
not only adds to astroglial heterogeneity and plasticity but also
hints at many more subtypes of astrocytes operational in healthy
and pathological nervous tissue.
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Fig. 1 Anti-inflammatory astrocytes. The subpopulation of anti-
inflammatory astrocytes is present in the spinal cord of mice and
possibly of humans.5 These astrocytes specifically express the lysosomal
associated protein 1 (LAMP1) and the death receptor ligand TRAIL; the
latter after being released activate death receptors on T lymphocytes
instigating their apoptosis. Expression of TRAIL in astrocytes is
controlled by IFN-γ secreted by meningeal natural killer cells; IFN-γ
reaches astrocytic endfeet through subarachnoid cerebrospinal fluid.
The IFN-γ natural killer cells are, in their turn, under control from
systemic factors including the gut microbiome; depletion of the latter
substantially reduces the number of IFN-γ secreting natural killer cells
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